Viral Filtration: A Review of Current and Future Practices in
Bioprocessing
- Sarah Johnson,
- Shuang Chen,
- Glen Bolton,
- Qi Chen,
- Scott Lute,
- John Fisher,
- Kurt Brorson
Sarah Johnson
FDA
Corresponding Author:sarah.johnson1@fda.hhs.gov
Author ProfileAbstract
For drug products manufactured in mammalian cells, safety assurance
practices are needed during production to assure that the final
medicinal product is safe from the potential risk of viral
contamination. Virus filters provide viral retention for a range of
viruses through robust, size-based retention mechanism. Therefore, a
viral filtration step is commonly utilized in a well-designed
recombinant therapeutic protein purification process and is a key
component in an overall strategy to minimize the risks of adventitious
and endogenous viral particles during the manufacturing of biotechnology
products. This review summarizes the history of viral filtration,
currently available viral filters and prefilters, and viral filtration
integrity test methods and study models. There is also discussion of
current understanding and gaps with an eye toward future trends and
emerging filtration technologies.02 Aug 2021Submitted to Biotechnology and Bioengineering 03 Aug 2021Submission Checks Completed
03 Aug 2021Assigned to Editor
09 Aug 2021Reviewer(s) Assigned
01 Sep 2021Review(s) Completed, Editorial Evaluation Pending
01 Sep 2021Editorial Decision: Revise Major
03 Nov 20211st Revision Received
05 Nov 2021Submission Checks Completed
05 Nov 2021Assigned to Editor
05 Nov 2021Reviewer(s) Assigned
15 Nov 2021Review(s) Completed, Editorial Evaluation Pending
15 Nov 2021Editorial Decision: Revise Minor
30 Nov 20212nd Revision Received
02 Dec 2021Submission Checks Completed
02 Dec 2021Assigned to Editor
02 Dec 2021Review(s) Completed, Editorial Evaluation Pending
02 Dec 2021Editorial Decision: Accept